Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | Novel therapeutic for AML: fadraciclib combinations

Mhairi Copland • 7 Dec 2019
ASH 2019
Acute Myeloid Leukemia Leukemia Azacitidine Cytarabine Fadraciclib Venetoclax

Mhairi Copland, PhD, MBChB, FRCP, FRCPath, Paul O’Gorman Leukaemia Research Centre, University of Glasgow, Glasgow, UK, outlines a study that aimed to assess the effects of fadraciclib, a novel CDK2/9 inhibitor, on the growth and survival of acute myeloid leukemia (AML) cells. The study also evaluated the synergistic effect of fadraciclib in combination with other targeted or chemotherapy agents. Results show that fadraciclib pulse treatment effectively induced apoptosis in AML cell lines in vitro and a synergistic effect of fadraciclib in combination with venetoclax, cytarabine or azacitidine was observed. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Mhairi Copland

Co-targeting in CML: practical considerations & the potential of the bone marrow microenvironment
3:00
Co-targeting in CML: practical considerations & the potential of the bone marrow microenvironment
Mhairi Copland • 4 Sep 2025
How the management of CML is evolving & future directions
1:18
How the management of CML is evolving & future directions
Mhairi Copland • 5 Sep 2025
Current and future treatment strategies for blast-phase CML
3:05
Current and future treatment strategies for blast-phase CML
Mhairi Copland • 29 Sep 2022
The importance of improving treatment-free remission in patients with CML
1:36
The importance of improving treatment-free remission in patients with CML
Mhairi Copland • 29 Sep 2022

Related Videos

Addressing changes to genomic prognostic markers in CLL beyond the chemotherapy era
4:04
Addressing changes to genomic prognostic markers in CLL beyond the chemotherapy era
Anna Schuh • 16 Oct 2026
Understanding the CLL genome: current knowledge and remaining gaps
3:39
Understanding the CLL genome: current knowledge and remaining gaps
Anna Schuh • 16 Oct 2026
How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
2:00
How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
Alexey Danilov • 16 Oct 2026
Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
3:39
Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
Marta Coscia • 16 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals